)
Brainstorm Cell Therapeutics (BCLI) investor relations material
Brainstorm Cell Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Focused on developing autologous cell therapies for neurodegenerative diseases, with NurOwn® as the lead candidate for ALS, PMS, and AD.
Advanced pre-initiation activities for the Phase 3b ENDURANCE trial of NurOwn in ALS after FDA clearance, aiming to enroll 200 participants with a 24-week double-blind and 24-week open-label extension period.
Engaged with clinical sites, manufacturing partners, and regulatory authorities to ensure operational readiness for the upcoming trial.
A Citizen Petition was filed with the FDA by ALS community representatives, requesting renewed regulatory review of NurOwn data; the company acknowledged but did not participate in the petition.
Company delisted from Nasdaq in July 2025 due to non-compliance with minimum shareholder equity, now trading on OTCQB.
Financial highlights
Net loss for Q3 2025 was $2.1M, down from $2.7M in Q3 2024; net loss for nine months ended September 30, 2025 was $7.9M, down from $8.7M year-over-year.
Operating expenses for nine months ended September 30, 2025 were $7.7M, down from $8.5M year-over-year.
Cash, cash equivalents, and restricted cash at September 30, 2025 totaled $236K.
Net cash used in operating activities for nine months ended September 30, 2025 was $6.2M; net cash provided by financing activities was $6.1M.
Net loss per share for Q3 2025 was $0.19, improved from $0.51 in Q3 2024.
Outlook and guidance
Management expects continued operating losses and negative cash flow from clinical and regulatory activities.
Additional capital will be required to fund Phase 3b ALS trial and commercialization efforts.
Uncertainty remains regarding the ability to raise future financing, especially after delisting from Nasdaq.
Planning to host a conference call and webcast in late Q4 2025 or early Q1 2026 to provide further updates on the NurOwn Phase 3 program.
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)